EPISODIC MIGRAINE (ADVANCE STUDY)
QULIPTA demonstrated efficacy data for proportion of patients with ≥75% reduction in MMD and proportion of patients with 100% reduction in MMD1*
Adapted from the QULIPTA Product Monograph.
Safety information
Click here for additional safety information and for a link to the Product Monograph discussing:
●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, hypersensitivity reactions, pregnant and nursing women, and geriatrics.
●Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.
Reference:
1. QULIPTA Product Monograph. AbbVie Corporation.
MMD: monthly migraine days.
* The ADVANCE trial was a phase 3, double-blind, multicentre, randomized, placebo-controlled trial of 910 patients who, after a 28-day baseline period, were randomized 1:1:1:1 to receive QULIPTA (10/30/60 mg) or placebo once daily for 12 weeks.1
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
MMD: monthly migraine days.
* The ADVANCE trial was a phase 3, double-blind, multicentre, randomized, placebo-controlled trial of 910 patients who, after a 28-day baseline period, were randomized 1:1:1:1 to receive QULIPTA (10/30/60 mg) or placebo once daily for 12 weeks.1
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 888 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-QLP-240063A / OC24